Effect of Gabapentin on Orthopedic Pain
Degenerative Joint Disease of Hip and Knee.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||The Effect of Gabapentin on Postoperative Pain: a Randomized, Double Blind, Placebo Controlled Trial|
- The primary endpoint will be opioid consumption [ Time Frame: 48 hours ] [ Designated as safety issue: No ]Total opioid consumption and lowest/highest pain score in 8 hour segments.
- sleep scales [ Time Frame: 48 hours post operatively ] [ Designated as safety issue: No ]Pittsburgh Sleep Quality Index.
|Study Start Date:||March 2012|
|Estimated Study Completion Date:||August 2016|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Placebo Comparator: placebo
Placebo one dose in the evening of surgery and post op day #1.
Active Comparator: Gabapentin
Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively
400mg orally at 9pm day of surgery and the first evening post operatively.
Other Name: Neurontin
Hide Detailed Description
Recent studies have also supported the use of gabapentin as an adjuvant medication in postoperative pain management. Gabapentin decreased the pain associated with movement in post-mastectomy patients. Gilron et al showed a combination of gabapentin and rofecoxib superior to either medication alone in relieving pain after hysterectomy. Later, Gilron et al showed that adding meloxicam to gabapentin in patients undergoing outpatient laparoscopic surgery provided little additional benefit. Clarke et al demonstrated the decrease in the use of opioids in patients who received preoperative and postoperative gabapentin after total knee arthroplasty. They also noted that optimum timing and dosage of the gabapentin needed to be further elucidated. However, in the same year, Clarke et al also reported that gabapentin provided no benefit after total hip arthroplasty when a robust multimodal analgesic regimen was combined with spinal anesthesia. The side effects of gabapentin include sleepiness, which may be of benefit in the postoperative period. In a meta-analysis, Peng showed a 35 % decrease in total opioid consumption in the first 24 hours postoperatively. However, they did note an increase in sleepiness and dizziness. While a recent investigation did not find a connection between sleep disturbances and postoperative pain, a questionnaire study found that the most common reason for nighttime awakenings was pain, and that analgesia was the most helpful intervention. Gabapentin, a structural analogue to y-aminobutyric acid, has been shown in healthy subjects to increase SWS; maintain a stable REM; and reduce arousals, awakenings, and stage shifts—all of which are features of sleep fragmentation. Gabapentin is currently used to treat epilepsy, diabetic neuropathy, postherpetic neuralgia, as well as restless legs syndrome, and its effect on sleep patterns may attribute to its therapeutic success with these disorders Sleep deviates from the normal sleeping pattern in the postoperative patient. Total sleep time, proportion of REM sleep, and proportion of slow wave sleep (SWS) are all reduced. Sleep postoperatively tends to be highly fragmented with multiple spontaneous awakenings and movement arousals. Most of these changes occur during postoperative days 1 and 2; however, patients also incur a REM sleep rebound in days 3 and 4 that can extend up to a week. Studies have demonstrated that these postoperative sleep disturbances, notably the prolonged REM sleep rebound, may contribute to the development of altered mental function, postoperative episodic hypoxemia, and hemodynamic instability. A recent study even found that postoperative sleep disruptions independently predicted functional limitations three months following surgery in patients who underwent total knee replacement. The pathogenesis of these sleep changes appears to be strongly correlated to the magnitude of the surgery as opposed to the type of anesthesia used. Many specific mediators of surgical stress response have been indicated, including catecholamines, cortisol, and IL-1; however, as REM sleep is controlled by many regions of the brain, disturbances may be due to a global excitatory CNS effect.
Our study will recruit 90 patients between the ages of 18 and 70 who are undergoing total hip arthroplasty, hip fracture repair, or total knee arthroplasty and have been assigned an ASA rating of I-III, who are not pregnant. After Institutional Review Board approval, a written informed consent will be obtained from the patient. The study protocol, use of the Patient Controlled Analgesia (PCA) pump, sleep scale, sedation scale, and visual analogue scale for pain will all be explained. Demographic information will be obtained including age, gender, past medical history, past surgical history, hospitalizations, current medications, allergies, and history of drug and alcohol abuse. In addition, a preoperative sleep history will be obtained using the Pittsburgh Sleep Quality Index (PSQI) [14, 15]. The 50 patients will be randomized into two groups: (1) placebo, (2) gabapentin. An Excel generated randomization schedule will be employed. The dosage of gabapentin administered will be 400mg.
Prior to surgery, all patients will be administered midazolam 1-3mg IV to achieve anxiolysis. They will also receive a lumbar plexus block or a femoral nerve block, depending on the surgery to be done, as this has become the standard of care for orthopedic patients at University Hospital. All patients will receive celecoxib 200 mg po bid for three postoperative days. In the operating room, standard general anesthesia technique will be utilized. Upon extubation, the patient will be transferred to the postanesthesia care unit (PACU), where baseline pain and sedation scores will be obtained using the Visual Acuity Scale (VAS), the Richmond Agitation Sedation Scale (RASS), and Ramsay Sedation Scale (RSS), respectively. All pain scores will be assessed with subjects in the resting position. A continuous infusion of bupivacaine 0.125mg/L will be started at a rate of 10mL/hr and continued to postoperative day 2. An I.V. PCA hydromorphone pump will be initiated and set to deliver a 0.2mg bolus per demand with a 5 minute lockout and no background infusion. All patients will be instructed to maintain their VAS pain score at less than 4 out of 10. If the VAS pain score is 5 or greater at rest on two consecutive pain assessments, the dose of intravenous PCA hydromorphone will be increased to deliver a 0.3mg bolus per demand.
At approximately 9pm on the day of the procedure the first dose of placebo/gabapentin will be given. The gabapentin or placebo treatment will be given once more at 9 pm on postoperative day 1. The surgical team will be asked not to order any additional medication for sleep. The following mornings, on POD1 and POD2, a questionnaire addressing the quality of sleep, hours of sleep, number of awakenings throughout the night, and contributing reasons for these awakenings (pain, noise, urination, temperature discomfort, positional discomfort, for nursing care, or other reasons) will be given. Patients will also be assessed for pain, sedation, as well as the incidence of any side effects, including nausea, vomiting, dizziness, and pruritus. In addition, all patients will begin an as-tolerated weight-bearing rehabilitation program for range of motion, strengthening, balance and ambulation beginning the first day after surgery. Success in completion of the physical therapy goals of being out of bed in a chair by postop day 1 and ambulating by postop day 2 will be determined for each group.
The purpose of this study is to determine if a single dose of gabapentin decrease patients' postoperative pain. The primary endpoint will be opioid consumption; additional assessments will include: subjective sleep scales, pain scores, and patient's ability to reach postoperative rehabilitation goals
Please refer to this study by its ClinicalTrials.gov identifier: NCT01546857
|United States, New Jersey|
|Newark, New Jersey, United States, 07101|
|Principal Investigator:||J. Daniel Eloy, MD||Rutgers/SUNJ|